Edition:
United Kingdom

Tocagen Inc (TOCA.OQ)

TOCA.OQ on NASDAQ Stock Exchange Global Select Market

8.91USD
8:21pm GMT
Change (% chg)

$0.18 (+2.06%)
Prev Close
$8.73
Open
$8.75
Day's High
$9.10
Day's Low
$8.49
Volume
47,299
Avg. Vol
83,778
52-wk High
$15.80
52-wk Low
$6.49

Latest Key Developments (Source: Significant Developments)

Tocagen Announces Pricing Of Public Offering Of Common Stock
Thursday, 13 Dec 2018 

Dec 12 (Reuters) - Tocagen Inc ::TOCAGEN ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 3 MILLION SHARES OF ITS COMMON STOCK AT A PRICE TO PUBLIC OF $10.00 PER SHARE.  Full Article

Tocagen Announces Proposed Public Offering Of Common Stock
Tuesday, 11 Dec 2018 

Dec 11 (Reuters) - Tocagen Inc ::TOCAGEN ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.TOCAGEN INC - COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF 3 MILLION SHARES.  Full Article

Tocagen Files For Offering Of Up To $30 Mln Of Common Stock-SEC Filing
Wednesday, 21 Nov 2018 

Nov 21 (Reuters) - Tocagen Inc ::TOCAGEN INC FILES FOR OFFERING OF UP TO $30.0 MILLION OF COMMON STOCK - SEC FILING.  Full Article

Tocagen Q3 Loss Per Share $0.02
Thursday, 8 Nov 2018 

Nov 8 (Reuters) - Tocagen Inc ::TOCAGEN REPORTS THIRD QUARTER 2018 FINANCIAL AND BUSINESS RESULTS.Q3 LOSS PER SHARE $0.02.Q3 EARNINGS PER SHARE VIEW $-0.45 -- THOMSON REUTERS I/B/E/S.TOCAGEN - ESTIMATES TOTAL CASH USED IN 2018 TO FUND OPERATIONS AND CAPEX WILL BE ABOUT $50 MILLION, RESULTING IN YEAR-END CASH BALANCE OF ABOUT $70 MILLION.CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $79.8 MILLION AT SEPT 30 VERSUS $88.7 MILLION AT DEC 31, 2017.  Full Article

Tocagen Reports Second Quarter 2018 Financial And Business Results
Tuesday, 7 Aug 2018 

Aug 7 (Reuters) - Tocagen Inc ::TOCAGEN REPORTS SECOND QUARTER 2018 FINANCIAL AND BUSINESS RESULTS.Q2 LOSS PER SHARE $0.81.Q2 EARNINGS PER SHARE VIEW $-0.59 -- THOMSON REUTERS I/B/E/S.PROJECTED YEAR-END 2018 CASH POSITION INCREASED TO APPROXIMATELY $70 MILLION.STRONG EXECUTION OF TOCA 5 PHASE 3 CLINICAL TRIAL WITH UPCOMING MILESTONES ON TRACK.  Full Article

Tocagen Entered Amended And Restated Loan And Security Agreement For $26.5 Mln
Wednesday, 23 May 2018 

May 23 (Reuters) - Tocagen Inc ::TOCAGEN - ENTERED AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT FOR $26.5 MILLION AS TERM LOANS FUNDED ON EFFECTIVE DATE - SEC FILING.  Full Article

Tocagen Reports Q1 Loss Per Share $0.65
Thursday, 10 May 2018 

May 10 (Reuters) - Tocagen Inc ::TOCAGEN REPORTS FIRST QUARTER 2018 FINANCIAL AND BUSINESS RESULTS.Q1 LOSS PER SHARE $0.65.  Full Article

Tocagen And ApolloBio Enter License Agreement To Develop Toca 511 & Toca FC In Greater China
Thursday, 19 Apr 2018 

April 19 (Reuters) - Tocagen Inc ::TOCAGEN AND APOLLOBIO ENTER LICENSE AGREEMENT TO DEVELOP AND COMMERCIALIZE TOCA 511 & TOCA FC IN THE GREATER CHINA REGION.TOCAGEN INC - TOCAGEN ELIGIBLE TO RECEIVE UP TO $127 MILLION IN UPFRONT PAYMENT, DEVELOPMENT AND COMMERCIAL MILESTONES.TOCAGEN - ELIGIBLE TO RECEIVE ADDITIONAL DOUBLE-DIGIT TIERED SALES ROYALTIES UPFRONT AND NEAR-TERM DEVELOPMENT MILESTONES PAYMENTS TOTAL UP TO $20 MILLION.TOCAGEN INC - WILL BE ELIGIBLE FOR ADDITIONAL FUTURE PAYMENTS TOTALING UP TO $111 MILLION UPON MEETING CERTAIN DEVELOPMENT AND COMMERCIAL MILESTONES.TOCAGEN INC - WILL BE RESPONSIBLE FOR ALL DEVELOPMENT AND COMMERCIALIZATION COSTS IN LICENSED TERRITORY.TOCAGEN INC - LICENSE GRANT TO APOLLOBIO IS EXPECTED TO BECOME EFFECTIVE IN Q2 OF 2018.  Full Article

Tocagen Q4 Loss Per Share $0.55
Thursday, 8 Mar 2018 

March 8 (Reuters) - Tocagen Inc ::TOCAGEN REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL AND BUSINESS RESULTS.Q4 LOSS PER SHARE $0.55.‍TOCAGEN ESTIMATES TOTAL CASH USED IN 2018 TO FUND OPERATIONS, CAPITAL EXPENDITURES AND DEBT AMORTIZATION WILL NOT EXCEED $50 MILLION​.‍CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $88.7 MILLION AT DECEMBER 31, 2017 COMPARED TO $31.2 MILLION AT DECEMBER 31, 2016​.  Full Article

Tocagen Estimates Cash, Cash Equivalents And Marketable Securities About $89.0 Million As Of Dec 31, 2017
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Tocagen Inc ::TOCAGEN SAYS ESTIMATE CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE ABOUT $89.0 MILLION AS OF DEC 31, 2017 - SEC FILING.TOCAGEN - ESTIMATE TOTAL CASH USED IN 2018 TO FUND OPERATIONS, CAPITAL EXPENDITURES, DEBT AMORTIZATION TO NOT EXCEED $50.0 MILLION.  Full Article